#PostpartumMalaria #MalariaPrevention #MaternalRisk #Artemisinin
#InnovativeStrategy #PublicHealth #EndemicAreas
In
regions with high malaria prevalence,
pregnant women are a high-risk group. Multiple targeted measures, such as
intermittent preventive treatment during pregnancy and prompt
management of
symptomatic episodes, can be implemented. However, after childbirth, malaria
prevention is often neglected—even though women remain vulnerable, and in some
cases, even more exposed than before. Recent studies show that the risk of
malaria increases in postpartum women compared to non-pregnant women. This is
explained by
pregnancy-related immune suppression, close contact with the baby,
and discontinuation of preventive treatments. This risk concerns both
symptomatic malaria and asymptomatic infections, which can worsen maternal
anemia and lead to complications for both mother and child.
Despite growing recognition of this problem,
international and national guidelines still focus mainly on the prenatal
period, and few protocols recommend active measures for the postpartum period.
This lack of consensus leaves thousands of women insufficiently protected, even
though postpartum malaria is associated with significant maternal morbidity,
especially in many endemic countries.
Given this context,
new prevention strategies
must be evaluated. Among them, the preventive administration of an
artemisinin-based combination therapy (ACT) at the time of delivery appears
promising. Widely used to treat malaria episodes, ACT could play a key role by
providing immediate protection during a period when maternal immunity is not
yet fully restored. Testing this innovative approach addresses an unmet
clinical and public health need, crucial for reducing the malaria burden among
postpartum women in high-risk areas.
ACT at delivery: shield or mirage?
To evaluate this new prevention strategy, an
open-label randomized controlled trial was conducted in Papua New Guinea, a
region with a high malaria burden. Healthy women who had just given birth were
assigned to two groups:
- One group
received no treatment;
- The other
group received a single course of ACT (either artemether-lumefantrine or
dihydroartemisinin-piperaquine).
Monthly follow-up was carried out for six
months, including systematic malaria screening and hemoglobin monitoring. The
primary objective was to measure the incidence of malaria confirmed by blood
smear in the six months following delivery.
The results show that administration of ACT at
delivery halved the risk of postpartum malaria (21% with ACT vs. 38% without
treatment), with equivalent efficacy between the two ACT regimens tested.
Improvement in hemoglobin levels was similar in both groups, indicating that
ACT does not provide additional benefit for correcting anemia. Furthermore, ACT
was well tolerated, causing only mild and transient side effects comparable to
those seen in untreated women. However, the rate of submicroscopic infections—detected
only by PCR—remained high in all groups.
Postpartum malaria: the end of a blind spot?
Postpartum malaria remains a frequent and
potentially severe condition in areas of high endemicity, contributing to both
maternal and infant morbidity. Despite progress made during pregnancy, the
period after childbirth continues to be marked by increased vulnerability in
the absence of specific preventive strategies. Major challenges include the
persistence of asymptomatic infections that are hard to detect, the lack of
postpartum recommendations in most protocols, and the need to adapt any
intervention to local contexts and health system capacities.
In this context, the aim of this study was to
evaluate the effectiveness of a single course of ACT administered immediately
after delivery in reducing the risk of malaria over the following six months.
The study also assessed the impact of this treatment on maternal anemia and its
safety.
Adding a
course of ACT at hospital discharge
appears to be a promising avenue to strengthen malaria prevention in postpartum
women. The results confirm that this treatment reduces the incidence of
postpartum malaria by half, with no significant effect on maternal anemia, and
that both regimens are well tolerated. However, protection declines beyond two
months, likely due to the pharmacokinetics of the drugs used. High rates of
submicroscopic infection and no benefit for anemia correction were noted.
In addition,
the intensive follow-up required by the study differs from usual practices in
the field, and the study does not resolve the issue of repeated or prolonged
dosing regimens. Further research is needed to determine the optimal strategy
(dose, frequency, target), test feasibility in real-world conditions, and
measure the long-term impact on maternal health. Tailoring interventions to
local contexts and
ensuring close follow-up will be essential to maximize
public health benefits.
Read next: A race against time for a vaccine?
